Allogene Therapeutics Inc
NASDAQ:ALLO
Allogene Therapeutics Inc
NASDAQ:ALLO
Price:
2.24
USD
-3.03%
Market Closed
Market Cap:
$503.4m
Relative Value
The Relative Value of one
ALLO
stock under the Base Case scenario is
hidden
USD.
Compared to the current market price of 2.24 USD,
Allogene Therapeutics Inc
is
hidden
.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
ALLO Relative Value
HIDDEN
Multiples Across Competitors
ALLO Competitors Multiples
Allogene Therapeutics Inc Competitors
Allogene Therapeutics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Allogene Therapeutics Inc
NASDAQ:ALLO
|
497.7m USD | 0 | -2.2 | -1.2 | -1.1 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
407.9B USD | 6.7 | 97.4 | 16 | 22.2 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
197.9B USD | 5.4 | 25.7 | 14.8 | 14.8 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
178.6B USD | 6.1 | 21 | 13.1 | 16.2 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
115.4B USD | 9.6 | 29.3 | 22 | 23 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80.4B USD | 5.6 | 17.8 | 13.3 | 15.2 | |
| AU |
|
CSL Ltd
ASX:CSL
|
70.5B AUD | 3.2 | 35.8 | 11.8 | 14.8 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
37.8B EUR | 10.8 | 34.7 | 37.6 | 38.4 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
